Holen Sie sich die Stockscreener-App
14.76
4.24%
0.60
Handel nachbörslich:
14.71
-0.05
-0.34%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.16
Offen:
$14.22
24-Stunden-Volumen:
1.57M
Relative Volume:
1.45
Marktkapitalisierung:
$679.15M
Einnahmen:
$159.01M
Nettoeinkommen (Verlust:
$-21.72M
KGV:
-28.38
EPS:
-0.52
Netto-Cashflow:
$-20.63M
1W Leistung:
+7.35%
1M Leistung:
+24.14%
6M Leistung:
-18.63%
1J Leistung:
+31.08%
1-Tages-Spanne:
$14.00
$14.76
1-Wochen-Bereich:
$13.50
$14.76
52-Wochen-Spanne:
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
Firmenname
Axogen Inc
Sektor
Branche
Telefon
(386) 462-6817
Adresse
13631 PROGRESS BLVD., ALACHUA, FL
Vergleichen Sie AXGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
14.76 | 651.54M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Lake Street | Buy |
| 2024-07-01 | Eingeleitet | Raymond James | Outperform |
| 2022-11-11 | Fortgesetzt | Jefferies | Buy |
| 2022-05-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-03-02 | Bestätigt | Lake Street | Buy |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Eingeleitet | Jefferies | Buy |
| 2017-11-21 | Bestätigt | Lake Street | Buy |
| 2017-07-31 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Eingeleitet | ROTH Capital | Buy |
| 2016-11-22 | Hochstufung | Lake Street | Hold → Buy |
| 2016-11-07 | Bestätigt | Wedbush | Outperform |
| 2016-11-03 | Herabstufung | Lake Street | Buy → Hold |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2014-05-14 | Eingeleitet | Dawson James | Buy |
| 2013-10-31 | Bestätigt | Ladenburg Thalmann | Buy |
Alle ansehen
Axogen Inc Aktie (AXGN) Neueste Nachrichten
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - Insider Monkey
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - Yahoo Finance
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com Australia
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Transcript : Axogen, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Axogen Boosts 2025 Revenue Growth Target to at Least 17% Ahead of BLA Approval. - AInvest
Axogen, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) - Seeking Alpha
Axogen (AXGN.O) Sees Sharp Intraday Spike—What’s Driving the Volatility? - AInvest
AxoGen's Q2 Earnings Exceed Expectations with Strong Financial TurnaroundNews and Statistics - IndexBox
Axogen Stock Soars 18.25% on Strong Q2 Earnings - AInvest
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
AxoGen Q2 revenue up 18.3%, beats estimates - MarketScreener
Axogen Inc earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Axogen's Q2 2025 Financial Outlook and Strategic Position in the Peripheral Nerve Repair Market - AInvest
Axogen, Inc. Reports Second Quarter 2025 Financial Results - The Manila Times
Should I hold or sell Axogen Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
Is it the right time to buy Axogen Inc. stockBreakthrough stock performance - Jammu Links News
Is Axogen Inc. a good long term investmentCapitalize on emerging investment opportunities - Jammu Links News
What catalysts could drive Axogen Inc. stock higher in 2025Spectacular growth rates - Jammu Links News
What institutional investors are buying Axogen Inc. stockConsistently high returns - Jammu Links News
What is the dividend policy of Axogen Inc. stockUnlock powerful market trend analysis - Jammu Links News
What are Axogen Inc. company’s key revenue driversAchieve consistent profits with expert advice - Jammu Links News
What markets is ENTX expanding into Is Axogen Inc. stock a good long term investment optionRemarkably fast returns - Jammu Links News
What are the latest earnings results for Axogen Inc.Build a strong portfolio for growth and safety - Jammu Links News
Finanzdaten der Axogen Inc-Aktie (AXGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):